Figure 4From: Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging studyPhysician's and patient's global assessment of response and clinical signs of inflammation (72 hours post-dose).Back to article page